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Staphylococcal a-toxin is a cytolytic toxin secreted
by many strains of Staphylococcus aureus that has
proin£ammatory and cytotoxic e¡ects on human
keratinocytes. a-toxin exerts its e¡ects by forming a
transmembrane pore that behaves like an ionophore
for ions such as calcium. Because cellular membrane
disruption with resultant intracellular calcium mobili-
zation is a potent stimulus for the synthesis for the lipid
mediator platelet-activating factor, the ability of a-tox-
in to induce platelet-activating factor production was
assessed, and whether the epidermal platelet-activating
factor receptor could augment toxin-induced signaling
in epithelial cells examined. Treatment of the human
keratinocyte-derived cell line HaCaT with a-toxin
resulted in signi¢cant levels of platelet-activating factor,
which were approximately 50% of the levels induced
by calcium ionophore A23187. a-toxin also stimulated
arachidonic acid release in HaCaT keratinocytes. Pre-
treatment of HaCaTcells with platelet-activating factor
receptor antagonists, or overexpression of the platelet-
activating factor metabolizing enzyme acetylhydrolase
II blunted a-toxin-induced arachidonic acid release
by approximately one-third, suggesting a role for
toxin-produced platelet-activating factor in this pro-
cess. Finally, retroviral-mediated expression of the
platelet-activating factor receptor into the platelet-
activating factor receptor-negative epithelial cell line
KB resulted in an augmentation of a-toxin-mediated
intracellular calcium mobilization and arachidonic
acid release. These studies suggest that a-toxin-
mediated signaling can be augmented via the epidermal
platelet-activating factor receptor. Key words: arachi-
donic acid/calcium/platelet-activating factor/staphylococcal
a-toxin. J Invest Dermatol 120:789 ^794, 2003
P
latelet-activating factor (1-O-alkyl-2-acetyl-glycero-3-
phosphocholine; PAF) is a glycerophosphocholine-
derived mediator with diverse pathophysiologic func-
tions, including platelet and leukocyte activation, air-
ways constriction, and vascular hyperpermeability (re-
viewed by Prescott et al, 2000). PAF is thought to exert its e¡ects
via interaction with its G-protein-coupled receptor (reviewed by
Ishii and Shimizu, 2000). Although PAF is the best characterized
ligand for the PAF receptor (PAF-R), other natural products can
bind to and signal through this receptor. These other ligands in-
clude oxidized phospholipids derived from low-density lipopro-
teins (Marathe et al, 1999), lipopolysaccharide and protein A
(Nakamura et al, 1992), lipotechoic acid moeities on streptococcus
and staphylococcus bacteria (Cundell et al, 1995; Lemjabbar and
Basbaum, 2002), and 1-acyl-2-acetyl glycerophosphocholine
(GPC) (Triggiani et al, 1991; Travers et al, 1998a). This diversity of
ligands recognized by the PAF-R could potentially allow invol-
vement of this system in a wide range of pathologic conditions,
including oxidative damage and bacterial infection.
Recent studies suggest that the PAF system is involved in ker-
atinocyte function and skin in£ammation. Indeed, PAF is found
in association with in£ammatory skin diseases (Grandel et al, 1985;
Mallet and Cunningham, 1985; Travers et al, 1998a), and intra-
dermal injections of PAF induce in£ammation (Markey et al,
1990;Travers et al, 1998a, b). Human keratinocytes both synthesize
PAF and 1-acyl PAF species as well as express functional PAF-R
(Michel et al, 1990; Travers et al, 1995, 1996). Activation of the epi-
dermal PAF-R leads to the production of PAF, prostaglandins,
interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-a, and
the inducible form of cyclooxygenase (cyclooxygenase type 2)
(Pei et al, 1998; Dy et al, 1999;Walterscheid et al, 2002).
Keratinocytes synthesize PAF from 1-O-alkyl GPC by the sub-
sequent actions of phospholipase A2 and acetyltransferase (Michel
et al, 1990; Travers et al, 1996). Stimuli for PAF production in ker-
atinocytes include calcium ionophores, cytokines such as IL-8,
pro-oxidative stressors, including ultraviolet B, and noxious
stimuli such as heat and cold exposure su⁄cient to induce cell
damage (Michel et al, 1990; Travers et al, 1996, 1999; Alapatt et al,
2000). Many of the above stimuli have in common the ability to
induce an intracellular calcium mobilization response.
Skin infections with Staphylococcus aureus are an important
cause of morbidity and even mortality. Infections by these bac-
teria not only cause disease directly, but are thought to be impor-
tant triggers in worsening in£ammatory skin diseases ranging
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from atopic dermatitis to psoriasis (reviewed by Leung et al, 1998).
One mechanism by which S. aureus can accomplish this is
through the production of soluble proteins with potent immuno-
modulatory e¡ects, including superantigens, protein A, and a-
toxin (reviewed byTravers et al, 2001).
Staphylococcal a-toxin is released by bacteria as a 293 residue
single chain polypeptide. Upon interaction with a target cell,
monomers of a-toxin polymerize to form a heptamer, which re-
sults in the formation of a transmembrane pore (Song et al, 1996).
The transmembrane pore causes membrane damage as well as an
in£ux of extracellular calcium, a potent damage-related stimulus
for many cells. Similar to calcium ionophores such as A23187,
small amounts of a-toxin result in signaling and potential repair-
able damage, whereas larger amounts result in cell death.
In primary cultures of endothelial cells, and rat pheochromo-
cytoma PC-12 cells, a-toxin activates phospholipase A2 via a cal-
cium-dependent process (Fink et al, 1989). Consistent with the
ability of a-toxin to activate phospholipase A2, this toxin has
been reported to stimulate arachidonic acid release and PAF
biosynthesis in endothelial cells (Suttorp et al, 1992; Grimminger
et al, 1997).
The objective of these studies was to assess whether the epider-
mal PAF-R could serve as a target for a-toxin through toxin-
mediated PAF production. Using epithelial cell lines, we present
evidence indicating that a-toxin is a powerful stimulus for
PAF biosynthesis, and that a-toxin-induced intracellular calcium
mobilization and arachidonic acid release can be modulated
by activation of the epidermal PAF-R. These ¢ndings suggest
a potential mechanism involving the PAF system by which
bacterial products can exert immunomodulatory e¡ects.
MATERIALS AND METHODS
Reagents Routine chemicals, PAF, and fatty acid-free bovine serum
albumin were obtained from Sigma (St Louis, MO). Growth media and
supplements were purchased from Life Technologies (Gaithersburg, MD)
and fetal bovine serum from Intergen (Purchase, NY). The PAF-R
antagonists were kindly provided as follows:WEB-2086 from Boehringer
Ingelheim (Ridge¢eld, CT), CV-6209 fromTakeda Chemical, Ltd. (Tokyo,
Japan), and A-85783 from Dr James Summers, Abbot Pharmaceuticals
(Abbott Park, IL). Staphylococcal a-toxin was provided by Toxin
Technologies, Inc. (Birmingham, Alabama). Staphylococcal a-toxin from
a recent clinical isolate of S. aureus was also puri¢ed to homogeneity, as
tested by sodium dodecyl sulfate^polyacrylamide gel electrophoresis, by
precipitation with 75% saturated (¢nal concentration) ammonium sulfate
followed by preparative thin layer isoelectric focusing in pH gradients of
3.5^10 and then 6^8 (Dinges et al, 2000). The toxin migrated as a major
protein with an isoelectric point between 7 and 8; other a-toxin protein
bands were also detected but were not collected. Puri¢ed a-toxin was
highly hemolytic for rabbit erythrocytes, was lethal for two of two
rabbits in 1 min at a dose of 1 mg per kg, and reacted with hyperimmune
anti-sera previously raised against the toxin.
Cells The human epithelial cell lines HaCaT and KB were cultured as
previously described (Travers et al, 1996; Pei et al, 1998). KB cells were
transduced with the MSCV2.1 retrovirus containing the human leukocyte
PAF-R cDNA as previously described (Travers et al, 1998a; Pei et al, 1998).
KB cell clones transduced with PAF-R (KBP) or with control MSCV2.1
retrovirus (KBM) were previously characterized by southern and northern
blot analysis and by binding and calcium mobilization studies to
demonstrate that the KB PAF-R was functional (Pei et al, 1998; Travers
et al, 1998a). All experiments were replicated with at least two to three
di¡erent KBP or KBM clones.
HaCaT cells overexpressing the enzyme PAF-AHII were created as
described previously (Marques et al, 2002). Brie£y, the entire PAF-AHII
cDNA was cloned into the MSCV2.1 retroviral vector, and HaCaT cells
were transduced with MSCV2.1PAF-AHII or empty MSCV2.1 retrovirus
(as control). Cells were screened with G418. Immunohistochemical studies
revealed increased PAF-AHII protein, and enzymatic assays demonstrated
an approximately 3-fold increase in PAF-AH activity in HaCaTMPAF-
AHII over control HaCaTM cells (Marques et al, 2002).
Measurement of PAF species and arachidonic acid PAF species
were measured by gas chromatography-mass spectrometry as previously
described (Travers et al, 1996; Alapatt et al, 2000). Brie£y, HaCaT
keratinocytes were plated into 10 cm dishes 48 h before use and were
85^95% con£uent. The media was removed and cells were washed three
times with Hank’s balanced salt solution. Various doses of a-toxin were
placed into 5 ml of Hank’s balanced salt solution and incubated with cells
for various times at 371C. At the appropriate time, the media was discarded
and cells harvested by addition of 4 ml of ice-cold ethanol. The plates were
scraped and contents placed into tubes containing 2 ng of deuterium-
labeled 1-hexadecyl and 1-palmitoyl sn-2 acetyl GPC species. The lipids
were isolated and subjected to gas chromatography mass spectrometry as
previously described (Travers et al, 1996). Arachidonic acid released into
the supernatants of a-toxin in 0.25% fatty acid-free bovine serum
albumin were measured by select ion monitoring gas chromatography-
mass spectrometry with deuterated arachidonic acid internal standard as
described previously (Travers et al, 1997; Pei et al, 1998). Experiments
typically were conducted with duplicate samples.
Intracellular calcium measurements Intracellular free calcium
concentrations, [Ca2þ ]i, in KB cells plated on glass coverslips were
assessed using the calcium-sensitive £uorescent dye indo-1/AM (Molecular
Probes, Eugene, OR) as previously reported (Pei et al, 1998).
Statistics Data are presented as the mean7SD. Statistical signi¢cance is
assessed by the Student’s t test and signi¢cance is set at po0.05.
RESULTS
The e¡ect of a-toxin on HaCaT PAF species production The
ability of staphylococcal a-toxin to stimulate the biosynthesis of
sn-2 acetyl GPC species in HaCaT keratinocytes was assessed
using a sensitive and speci¢c gas chromatography-mass spectro-
metry protocol using deuterated internal standards. As our
previous studies have demonstrated that essentially all PAF
species are cell associated rather than released into the supernatant
(Travers et al, 1996, 1997), only cell-associated species were
measured. As shown in Fig 1, a-toxin treatment of HaCaT
keratinocytes resulted in the generation of signi¢cant levels of
1-hexadecyl and 1-palmitoyl sn-2 acetyl GPC species. Increased
levels of sn-2 acetyl PAF species were ¢rst measured by 2.5 min,
were maximal at 10 min, and levels returned to baseline by
30 min (Fig 1A). Treatment of HaCaT keratinocytes with doses
of a-toxin greater than 2.5 mg per ml did not seem to result in
greater increases in PAF production (Fig 1B). Levels of a-toxin-
induced PAF species compare favorably with levels induced by
calcium ionophore A23187 (1.2 ng per 106 cells for 5 mg a-toxin
per ml vs 2.2 ng per 106 cells for 2 mM A23187 at 10 min). Though
a-toxin treatment resulted in signi¢cant PAF biosynthesis,
treatment of HaCaT cells with 1 mg per ml of the superantigen
toxin staphylococcal enterotoxin B did not result in increased
levels of sn-2 acetyl GPC species (data not shown).
The next studies examined the ability of a-toxin to induce
arachidonic acid release in HaCaT keratinocytes. Treatment
of HaCaT cells with 2.5 mg a-toxin per ml resulted in
measurement of signi¢cant levels of arachidonic acid in the
supernatant (Fig 2). Incubation of a-toxin with HaCaT
keratinocytes in calcium-free Hank’s balanced salt solution
with 1 mM ethylenediamine tetraacetic acid blocked arachi-
donic acid release as well as production of sn-2 acetyl GPC
species, indicating that a-toxin was inducing its e¡ects on
lipid mediator production through its ability to act as a Ca2þ
ionophore (Table I).
As a-toxin stimulates the production of signi¢cant levels of
PAF species, and activation of the PAF-R can cause arachidonic
acid release (Travers et al, 1997; Pei et al, 1998), the role of the
epidermal PAF-R in a-toxin-mediated arachidonic acid release
was next evaluated. First, the ability of PAF-R antagonists to
inhibit a-toxin-induced arachidonic acid release in HaCaT cells
was tested. As shown in Fig 3, preincubation of HaCaT
keratinocytes with the structurally dissimilar PAF-R antagonists
WEB2086 and A85789 partially inhibited a-toxin-mediated
arachidonic acid release. The maximum inhibition seen by the
highest doses of WEB2086 and A85789 were 3174% and
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3773% (mean7SEM from three separate experiments),
respectively.
Platelet-activating factor acetylhydrolases (PAF-AH) are a
family of phospholipases that degrade PAF and related species
(reviewed by Tjoelker and Sta¡orini, 2000). PAF-AHII is a
recently cloned member of this family that has been found to be
expressed in a variety of cell types, including keratinocytes
(Matsuzawa et al, 1997; Marques et al, 2002). To assess the role of
endogenous PAF production on a-toxin-mediated arachidonic
acid release, HaCaT keratinocytes were transduced with a
retrovirus encoding PAF-AHII (Marques et al, 2002). Enzymatic
assays revealed a 3-fold increase in spontaneous PAF-AH activity
in HaCaTMPAF-AHII cells over vector transduced control
HaCaTM cells (Marques et al, 2002). As shown in Fig 4, a-toxin
treatment of HaCaTMPAF-AHII cells resulted in signi¢cantly less
arachidonic acid release than control HaCaTM cells. Of note, the
level of inhibition [3176% (mean7SEM from three separate
experiments)] was similar to that induced by exogenous PAF-R
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Figure1. The e¡ect of staphylococcal a-toxin on PAF production in
HaCaT keratinocytes. (A) HaCaTcells were incubated with 2.5 mg a-tox-
in per ml, and the 1-hexadecyl and 1-palmitoyl sn-2 acetyl GPC species
were measured at various times as described in Materials and Methods. (B)
HaCaT cells were incubated with the indicated dosages of a-toxin for 5
min, and the 1-hexadecyl and 1-palmitoyl sn-2 acetyl GPC species were
measured. The values are expressed as mean7SEM of at least three to four
separate experiments using duplicate samples.
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Figure 2. The e¡ect of staphylococcal a-toxin on arachidonic acid
release in HaCaT keratinocytes. HaCaT cells were incubated with 2.5
mg a-toxin per ml, and supernatant-associated arachidonic acid was mea-
sured at various times as described in Materials and Methods. Each value is
the mean7SEM of at least three separate experiments using duplicate
samples.
Table I. E¡ect of extracellular calcium on a-toxin-mediated
PAF production and arachidonic acid release in HaCaT
keratinocytes.
HaCaTcells were treated with 2.5 mg a-toxin per ml in media with
calcium or in calcium-free media with 1 mM ethylenediamine tetra-
acetic acid. At 10 min 1-hexadecyl-2-acetyl GPC was measured in
cells, and supernatant-associated arachidonic acid measured after 60
min. The values are mean7SEM of two separate experiments
Treatment Extracellular [PAF] (ng per [Arachidonic acid]
Ca2þ 106 cells) (ng per 106 cells)
Vehicle þ 0.0770.02 1.170.2
a-toxin þ 1.1070.10 76713
Vehicle ^ 0.0870.03 0.870.1
a-toxin ^ 0.1870.08 1276
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Figure 3. The e¡ect of PAF-R antagonists on a-toxin-induced ara-
chidonic acid release in HaCaT keratinocytes. HaCaT cells were pre-
incubated with either 10 mM or 25 mM of the PAF-R antagonistsWEB 2086
orA-85789 for 30 min before addition of 2.5 mg a-toxin per ml, and super-
natant-associated arachidonic acid was measured after 60 min The values
are mean7SD of duplicate experiments from a single experiment from
three experiments with similar results. nPretreatment of HaCaT cells with
25 mM WEB 2086 and 10 mM and 25 mM A-85789 resulted in a statistically
signi¢cant (po0.05) decrease in a-toxin-induced arachidonic acid release.
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antagonists. These studies suggest that the PAF-R can exert
a modest augmentation on a-toxin-induced arachidonic acid
release in HaCaT cells.
The KB PAF-R model system To assess better the role of the
PAF-R in epithelial function, our laboratory created a model
system of epithelial cells with/without the PAF-R. This system
utilizes the human epidermal cell line KB, which, unlike normal
human keratinocytes, does not express functional PAF-R (Travers
et al, 1995; Pei et al, 1998). A PAF-R-positive KB cell line was
created by transducing KB cells with the replication-defective
MSCV2.1 retrovirus containing the entire human PAF-R cDNA
(Travers et al, 1998a; Pei et al, 1998). By comparing the e¡ects of
a-toxin on both PAF-R-positive (KBP) and PAF-R-negative
(transduced with empty MSCV 2.1 retrovirus; KBM) KB cells,
the role of the PAF-R on signaling and arachidonic acid release
could be readily assessed.
Treatment of KB cells with a-toxin resulted in arachidonic
acid release; however, a-toxin was a more potent stimulus for
arachidonic acid release in KBP than KBM cells (Fig 5A).
Preincubation of KB cells with PAF-R antagonists WEB 2086
(10 mM; Fig 5B), A-87983 (10 mM; Fig 5B), or CV-6209 (1 mM;
not shown) inhibited a-toxin-mediated arachidonic acid release
in KBP but not KBM cells. These studies con¢rm the ability of
the epidermal PAF-R to amplify a-toxin-mediated arachidonic
acid release.
Augmentation of a-toxin-induced intracellular calcium
mobilization by the epidermal PAF-R Inasmuch as
intracellular calcium mobilization is a potent stimulus for the
synthesis of many mediators, including PAF and eicosanoids, the
next studies examined whether a-toxin-induced intracellular
calcium mobilization could be modulated by the epidermal
PAF-R. Addition of PAF to KB cells loaded with the £uorescent
dye Indo-1 resulted in an increase in intracellular Ca2þ levels
only in KBP, but not KBM cells (Fig 6). Yet endothelin-1
treatment of KBM cells resulted in an intracellular calcium £ux,
indicating that these cells have all the necessary intracellular
machinery necessary to induce such a response. Treatment of KB
cells with a-toxin resulted in Ca2þ mobilization responses in
both KBP and KBM cells. Unlike the very rapid response seen
with exogenous PAF or endothelin-1, which act via G-protein
receptors, the Ca2þ mobilization response to a-toxin was
delayed, as well as of longer duration. Consistent with the
ability of a-toxin to produce endogenous PAF, the response to
a-toxin was signi¢cantly greater in KBP vs KBM cells due to
PAF-R-dependent intracellular Ca2þ mobilization (Table II,
Fig 6). As shown in Table II, preincubation of KBP cells with
PAF-R antagonists WEB 2086, A-87983, CV-6209 resulted in a
decrease in a-toxin-induced peak Ca2þ mobilization to levels
found in PAF-R-negative KBM cells. PAF-R antagonists had
no e¡ect on a-toxin-mediated peak intracellular Ca2þ levels
in KBM cells. Altogether, these data validate the hypothesis that
a-toxin-induced responses are enhanced through concomitant
activation of the epidermal PAF-R.
DISCUSSION
Skin colonization and/or infection with S. aureus can have pro-
found e¡ects upon cutaneous in£ammation. One important me-
chanism by which S. aureus can induce in£ammatory responses is
through the production of proteins such as a-toxin. Inasmuch
as more than half of S. aureus isolates found on active lesions of
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Figure 4. E¡ect of overexpression of PAF-AHII on a-toxin-induced
arachidonic acid release in HaCaT keratinocytes. HaCaT cells trans-
duced with PAF-AHII (HaCaTMPAF-AHII) or control retrovirus (Ha-
CaTM) were treated with 2.5 mg a-toxin per ml, and supernatant-
associated arachidonic acid was measured after 60 min. The values are
mean7SD of duplicate samples from a single experiment from three ex-
periments with similar results. nTreatment of HaCaTMPAF-AHII cells
with a-toxin resulted in a statistically signi¢cant (po0.05) decrease in ara-
chidonic acid release over HaCaTM cells.
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Figure 5. E¡ect of PAF-R expression on a-toxin-induced arachido-
nic acid release in KB cells. (A) KB cells transduced with PAF-R (KBP)
or control retrovirus (KBM) were treated with 2.5 mg a-toxin per ml for
various times, and supernatant-associated arachidonic acid was measured at
various times. (B) KBM or KBP cells were preincubated with 25 mM of
PAF-R antagonists WEB 2086 or A-85789 for 30 min before treatment
with 2.5 mg a-toxin per ml, and supernatant-associated arachidonic acid
was measured after 60 min. The values are mean7SD of duplicate samples
from a single experiment from three experiments with similar results.
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atopic dermatitis produce a-toxin (Ezepchuk et al, 1996), the
biologic e¡ects of this toxin on skin cells have potential clinical
relevance in our understanding of the mechanisms of bacterial-
mediated skin in£ammation.
These studies provide evidence that the epidermal PAF-R may
be involved in staphylococcal a-toxin-induced responses. Treat-
ment of the human keratinocyte-derived cell line HaCaT with
a-toxin was found to result in arachidonic acid release and PAF
biosynthesis. Though 1-hexadecyl and 1-palmitoyl PAF species
were synthesized in approximately equal amounts, 1-hexadecyl
species is probably the more biologically relevant as it is approxi-
mately 100more potent than 1-palmitoyl species (Triggiani
et al, 1991; Travers et al, 1998a). The kinetics of a-toxin-mediated
production of these lipid mediators was similar to those resulting
from ionophore A23187 treatment in epidermal cells (Michel et al,
1990; Travers et al, 1996, 1997; Pei et al, 1998), except that the
a-toxin response was delayed by about 2 min, which is consistent
with the delay seen in the calcium mobilization studies (instead
of an almost immediate response by ionophore). This delay is
probably due to the time needed for the a-toxin pore assembly
process. Consistent with a-toxin behaving as a calcium iono-
phore, removal of extracellular Ca2þ abolished a-toxin-mediated
intracellular calcium mobilization (not shown), arachidonic acid
release and PAF biosynthesis (Table I).
In addition to demonstrating that a-toxin was a potent inducer
of PAF biosynthesis in HaCaT cells, these studies provide evi-
dence that a-toxin-mediated PAF production could augment the
e¡ects of this toxin. Indeed, pretreatment of HaCaT cells with a
panel of PAF-R antagonists and/or overexpression of the PAF
metabolizing enzyme PAF-AHII resulted in a modest diminish-
ment of a-toxin-mediated arachidonic acid release. In addition,
a-toxin was found to stimulate more arachidonic acid release
in KB cells transduced with the PAF-R (KBP cells) over the
PAF-R-negative control KBM cells. Consistent with the impor-
tance of calcium £ux in a-toxin-induced responses, treatment of
KB cells with this physiologic ionophore resulted in an enhanced
intracellular calcium mobilization in KBP over KBM cells. These
¢ndings ¢t with the proposed hypothesis that a-toxin-induced
signaling in epidermal cells can be augmented by the epidermal
PAF-R through endogenous PAF biosynthesis.
The current studies indicating that the epidermal PAF-R can
augment a-toxin-induced signaling, along with the recent ¢nd-
ings by Lemjabbar and Basbaum (2002) that lipotechoic acid
moeities on S. aureus can signal directly through the PAF-R ¢t
with the notion that the epidermal PAF system may act as an en-
dogenous ‘‘damage sensor’’. The ability of the epidermal PAF-R to
induce a number of pro-in£ammatory protein and lipid cyto-
kines, including tumor necrosis factor-a, IL-1, IL-8, IL-10, pros-
taglandin E2, and PAF itself (Travers et al, 1996; Pei et al, 1998; Dy
et al, 1999; Waltersheid et al, 2002) would make this receptor an
appropriate sensor to alert the immune system to cutaneous sta-
phylococcal infections. Though potentially a protective response,
epidermal PAF-R-generated cytokines in response to bacterial
products could potentially worsen skin diseases such as atopic
dermatitis. Inasmuch as certain populations are potentially more
susceptible to PAF e¡ects due to inherited or acquired PAF-acet-
ylhydrolase de¢ciencies (Miwa et al, 1988; Tjoelker and Sta¡orini,
2000), these ¢ndings may have clinical implications. It should be
noted that Japanese patients who lack the serum PAF-AH enzyme
have been reported to have more severe asthma than control
populations (Sta¡orini et al, 1999). These ¢ndings have signi¢-
cance as lung epithelial cells and ¢broblasts express PAF-R (Roth
et al, 1996; Lemjabbar and Basbaum, 2002), which can be activated
not only by PAF, but also by bacterial products including lipote-
choic acid (Lemjabbar and Basbaum, 2002).
Though these studies only examined a-toxin, other bacterial
products could potentially exert similar augmentative responses
via downstream signaling through the epidermal PAF-R. For ex-
ample, superantigenic bacterial enterotoxins have been reported
to trigger intracellular Ca2þ mobilization responses (and pre-
sumably PAF synthesis) in major histocompatibility complex II-
positive keratinocyte cell lines (Wakita et al, 1995); however, in
unstimulated (i.e., major histocompatibility complex II negative)
HaCaT cells we have found that 1 mg per ml of staphylococcal
enterotoxin B did not cause PAF biosynthesis or calcium £ux.
Thus, it would appear that bacterial products can exert e¡ects
via PAF-R activation, through either direct receptor binding (li-
potechoic acid, protein A, lipopolysaccharide), or indirectly
through the induction of PAF synthesis (Nakamura et al, 1992;
Cundell et al, 1995; Lemjabbar and Basbaum, 2002). Further stu-
dies are warranted to characterize the potential signi¢cance of
these interactions.
In summary, these studies demonstrate a potential mechanism
by which staphylococcal bacteria can induce keratinocyte re-
sponses and thus induce in£ammation through the PAF-R. A
Figure 6. E¡ect of a-toxin on intracellular calcium levels in KB
cells. KBM or KBP cells were loaded with the calcium-sensitive dye
Indo-1 and treated with 100 nM PAF, 1 mM endothelin-1 (ET-1), or 2.5 mg
a-toxin per ml (a-T). Intracellular Ca2þ levels were calculated at the var-
ious times from £uorescent values as previously described (Pei et al, 1998).
Table II. E¡ect of PAF-R antagonists on a-toxin-induced
intracellular calcium mobilization in KB cells
Cell type Stimulus Peak D[Ca2þ]i
KBM a-toxin 4775 nM
KBM WEB 2086þa-toxin 5176 nM
KBM A-85789þa-toxin 4573 nM
KBP a-toxin 129713 nM
KBP WEB 2086þa-toxin 68710 nM
KBP A-85789þa-toxin 5877 nM
KBM or KBP cells loaded with the calcium-sensitive dye Indo-1were preincu-
bated with either 10 mM of WEB 2086, A-85789, or 0.1% dimethyl sulfoxide
vehicle 2 min before addition of 2.5 mg a-toxin per ml. Peak levels of intracellular
calcium increase were determined, and subtracted from baseline levels to obtain
D[Ca2þ]i. The values are mean7SEM from ¢ve to seven separate experiments
run typically in duplicate.
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better understanding of the functions of the PAF system in kera-
tinocyte biology and cutaneous in£ammation may lead to thera-
peutic interventions designed around this lipid mediator.
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